A new AI-powered voice analysis system is much more accurate than the current standard of care, according to new data presented at AHA Scientific Sessions 2026. The technology was specifically built to be user-friendly, requiring patients to speak just a handful of sentences into their smartphone each day.
The UltiSynq defibrillation lead from Abbott gives clinicians a new option for left bundle branch area pacing. The device has also received CE mark approval.
While quality-of-life improvements were seen in patients with regular chest pain, an invasive treatment strategy was not associated with a significant improvement in survival compared to patients treated more conservatively.
The FDA is now requiring labeling updates for all GLP-1 medications due to a risk of NAION, a rare eye condition that can result in sudden, permanent vision loss.
This represents the first randomized trial focused on treating moderate aortic stenosis with Medtronic's self-expanding, supra-annular Evolut platform.
Curtiss Stinis, MD, has been performing TAVR for nearly two decades. He says the new policies from CMS that expand coverage for asymptomatic patients represent a "momentous step forward" for heart patients with severe aortic stenosis.
